RJFSA
RPTX

Raymond James Financial Services Advisors’s Repare Therapeutics RPTX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-12,357
Closed -$149K – 3404
2023
Q3 		$149K Buy
+12,357
New +$128K ﹤0.01% 3004

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Raymond James Financial Services Advisors's RPTX Position: Q4 2023 in Review

Raymond James Financial Services Advisors sold out of Repare Therapeutics (RPTX) in Q4 2023, closing a stake of 12,357 shares — an estimated $149K sold.

Raymond James Financial Services Advisors first reported a position in RPTX in Q3 2023 and held it in 1 quarter. The position peaked at $149K in Q3 2023. 69 funds tracked by Wall St. Rank hold RPTX as of Q4 2023.

  • Raymond James Financial Services Advisors reported no remaining Repare Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 12,357 Repare Therapeutics shares in Q4 2023, an estimated $149K.
  • Raymond James Financial Services Advisors first reported a position in Repare Therapeutics in Q3 2023 and held it in 1 quarter.
  • Raymond James Financial Services Advisors's Repare Therapeutics position peaked at $149K in Q3 2023.
  • 69 funds tracked by Wall St. Rank held Repare Therapeutics as of Q4 2023.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2023, filed 16 Jan 2024.